CD274 and neoplasm: Additionally, Huang et al. and Roulleaux Dugage et al. highlighted the influence of the tumor immune microenvironment on immunotherapy efficacy, while Italiano et al. reported modest clinical outcomes in PD-1/PD-L1–targeted trials, with variable correlation with biomarker expression [49,50,51].